TIME magazine has named women's health specialist Sprout Pharmaceuticals among 10 organisations globally shaping the future of health and life sciences.
This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi.
In December 2025, the US Food and Drug Administration (FDA) approved an expanded indication for Addyi to include all women under 65 with Hypoactive Sexual Desire Disorder (HSDD), regardless of menopausal status, unlocking a significantly broader patient population and accelerating commercial expansion.
TIME evaluated companies based on impact, innovation, ambition, and success, selecting just 10 companies in health and life sciences as industry leaders.
AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer
Transcend Therapeutics acquired by Otsuka Pharmaceutical
Rocket Pharmaceuticals closes USD180m Rare Pediatric Disease voucher sale
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer
Formosa Pharmaceuticals signs Vietnam licensing deal with Samil Pharmaceuticals
Harbour BioMed IND for HBM7004 accepted by China's NMPA
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
FDA grants rare paediatric disease designation to RedHill's opaganib
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio
Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development
Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16
Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector